HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 CAR‐T (MB‐106) FOR OUTPATIENT TREATMENT OF FOLLICULAR LYMPHOMA (FL)—RESULTS OF A SINGLE‐INSTITUTION TRIAL

Overview of attention for article published in Hematological Oncology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 41,341 followers.

RT @mshadman: Day 3 of #17icml @icmlugano Oral presentation: MB-106, a 3rd gen CD20 autologous #CART for #FL @fredhutch https://t.co/l…

Day 3 of #17icml @icmlugano Oral presentation: MB-106, a 3rd gen CD20 autologous #CART for #FL @fredhutch https://t.co/lK5fLbtEMe

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.